Pharmacy

2:18
Self-administration of bortezomib in multiple myeloma: results from Cardiff
Tanya Burton
2:24
Accelerating clinical trials in transplantation
Charles Craddock
2:11
Regulatory approval of CPX-351 for secondary AML
Charles Craddock
2:14
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
Simon Cheesman
0:54
The switch to biosimilar rituximab at UCH: 12 months on
Simon Cheesman
1:42
Patient education is important for drug tolerance and adherence
Jeanne McCarthy-Kaiser
1:52
The role of the pharmacist in transplant
Jeanne McCarthy-Kaiser
3:17
A pharmacoeconomic analysis of multiple myeloma treatment
Rafael Fonseca
4:56
Value and cost in MM treatment
Vincent Rajkumar
1:08
Subcutaneous daratumumab: combining efficacy, safety & convenience
Ajai Chari
1:09
Treating GvHD: current challenges and newly approved drugs
Katie Gatwood
1:43
The importance of pharmacist intervention in the treatment of GvHD with ruxolitinib and ibrutinib
Katie Gatwood
2:29
Ruxolitinib and ibrutinib: the future for GvHD treatment?
Katie Gatwood
1:29
The CRUK Facilitator programme and NHS Lanarkshire pharmacists
Gillian Phillips
1:53
The introduction of novel immunotherapies and the pharmacist
Islam Elkonaissi
1:58
The importance of BOPA
Islam Elkonaissi
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals